PhenX - human papillomavirus vaccine use protocol 100801:-:Pt: Patient:-:PhenX - CISMeF
PhenX - human papillomavirus vaccine use protocol 100801:-:Pt: Patient:-:PhenXLOINC code
Preferred Label : PhenX - human papillomavirus vaccine use protocol 100801:-:Pt: Patient:-:PhenX;
LOINC status : TRIAL;
LOINC long common name : PhenX - human papillomavirus vaccine use protocol 100801;
LOINC short name : HPV vaccine use proto;
LOINC description : The interviewer asks the female participant whether she has ever received a human
papillomavirus (HPV) vaccination. If she answers yes, the interviewer asks her age
and how many shots she received. If the participant answers yes to question 1, the
interviewer should complete the rest of the protocol. If the participant answers no
then the protocol is deemed complete. The PhenX Working Group notes that GARDASIL
is also known as Silgard. European Medicines Agency. (September 25, 2009). Silgard
European Public Assessment Report. Retrieved from http://www.emea.europa.eu/humandocs/Humans/EPAR/silgard/silgard.htm.
Waknine, Yael. (October 2, 2006). International Approvals: Singulair and Gardasil/Silgard.
Medscape Today. Retrieved from http://www.medscape.com/viewarticle/545374.;